Результаты поиска

Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design.

AIMS: In univentricular hearts, selective lung vasodilators such as phosphodiesterase type 5 (PDE5) inhibitors would decrease pulmonary resistance and improve exercise tolerance. However, the level of evidence for the use of PDE5 inhibitors in patients with a single ventricle (SV) remains limited. We present the SV-INHIBITION study rationale, design, and methods. METHODS AND RESULTS: The SV-INHIBITION trial is a nationwide multicentre, randomized, double blind, placebo-controlled, Phase III study, aiming to evaluate the efficacy of sildenafil on the ventilatory efficiency during exercise, in

Совпадение в полном тексте источника
… planned during the study • Patient treated by any pulmonary arterial vasodilator drug, within 6 months before inclusion, regardless the duration and the type(s) (oral, intravenous, subcutaneous, or inhaled) of administration, such as sildenafil, tadalafil, riociguat, bosentan, macitentan, ambrisentan, epoprostenol …

Blockade of the purinergic P2Y12 receptor greatly increases the platelet inhibitory actions of nitric oxide.

Circulating platelets are constantly exposed to nitric oxide (NO) released from the vascular endothelium. This NO acts to reduce platelet reactivity, and in so doing blunts platelet aggregation and thrombus formation. For successful hemostasis, platelet activation and aggregation must occur at sites of vascular injury despite the constant presence of NO. As platelets aggregate, they release secondary mediators that drive further aggregation. Particularly significant among these secondary mediators is ADP, which, acting through platelet P2Y12 receptors, strongly amplifies aggregation. Platelet

Human lymphocytes stimulate prostacyclin synthesis in human umbilical vein endothelial cells. Involvement of endothelial cPLA2.

Prostacyclin (PGI2) contributes to the maintenance of a nonadhesive luminal surface in blood vessels due to its anti-platelet and vasodilatory properties. Here, we sought to determine whether peripheral blood lymphocytes (PBL) may regulate the PGI2 production of human umbilical vein endothelial cells (HUVEC). Cell-cell contact between HUVEC and lymphocytes markedly enhanced PGI2 synthesis as a function of the number of lymphocytes added. This stimulated synthesis was totally suppressed when lymphocytes and HUVEC were separated by a microporous insert. It was not due to prostaglandin H synthase

Pulmonary Hypertension in an Oncologic Intensive Care Unit

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… control in atrial fibrillation | AV blocks Use when ↓ LVEF Decreased pulmonary vascular resistance Inhaled NO | ↓ PVR | 10–40 ppm | Methemoglobinemia Hypotension Inhaled prostanoids Iloprost Treprostinil | ↓ PVR | 2.5–5 μg 6–9/day 6–54 μg QID | Hypotension, headache Flushing Jaw pain IV/SC prostanoids Epoprostenol …

Polypharmacy and medication use in patients with chronic kidney disease with and without kidney replacement therapy compared to matched controls.

BackgroundThis study aims to examine polypharmacy (PP) prevalence in patients with chronic kidney disease (CKD) Stage G4/G5 and patients with kidney replacement therapy (KRT) compared with matched controls from the general population. Furthermore, we examine risk factors for PP and describe the most commonly dispensed medications.MethodsDutch health claims data were used to identify three patient groups: CKD Stage G4/G5, dialysis and kidney transplant patients. Each patient was matched to two controls based on age, sex and socio-economic status (SES) score. We differentiated between 'all medic

Совпадение в полном тексте источника
… ATC code | Name A16AA05 | Cargluminezuur A16AB02 | Imiglucerase A16AB03 | Agalsidase Alfa A16AB04 | Agalsidase Beta A16AB10 | Velaglucerase Alfa A16AX06 | Miglustat B01AC09 | Epoprostenol B01AC21 | Treprostinil N07XX08 | Tafamidis Table A19. …

Acute and Chronic Respiratory Failure in Cancer Patients

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… If available prior to intubation, one may consider application of inhaled nitric oxide or inhaled epoprostenol to improve V/Q mismatch and augment RV unloading and LV filling [ 123 ]. …

Haematological Diseases in the Tropics

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Noted in up to 60% of SCD cases No relationship to acute chest syndrome (different pathophysiology) Mortality risk with even mild pulmonary hypertension is high Regular blood transfusions and long-term anticoagulation have been tried Hydroxycarbamide may decrease the risk Prostacycline analogues (epoprostenol …

ISEV2020 Резюме

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

CSI position statement on management of heart failure in India.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Р

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 31st Европейский педиатрический конгресс по педиатрии: часть 1.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме докладов 2017 Ежегодное совещание Общества общей внутренней медицины.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts from the 37th Annual Meeting of the Society of General Internal Medicine, 2014, San Diego, CA, USA.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.